Menu

Search

  |   Business

Menu

  |   Business

Search

Alcobra Ltd. to Present at Upcoming Investment Conferences

TEL AVIV, Israel, March 01, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced corporate presentations at the upcoming 28th Annual ROTH Conference and the Barclays Global Healthcare Conference.

28th Annual ROTH Conference 
Date:Monday, March 14
Time:1:00pm Pacific Time
Location:Ritz Carlton, Laguna Niguel, California
Presenter:David Baker, Chief Commercial Officer 


Barclays Global Healthcare Conference 
Date:Thursday, March 17
Time: 10:45am Eastern Time
Location:Loews Miami Beach Hotel, Miami, Florida
Presenter:Dr. Yaron Daniely, President & Chief Executive Officer
Webcast:https://cc.talkpoint.com/barc002/031516a_ae/?entity=72_U2Q8T5Q

About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice	
646-597-6979	
[email protected]

Media Inquiries	
Sam Brown, Inc.		
Mike Beyer	
773-463-4211		
[email protected]

Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
[email protected]

Primary Logo

  • Market Data
Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.